REG - Hemogenyx Pharma Plc - Exercise of Warrants and Issue of Equity

Hemogenyx PharmaceuticalsAnnouncement

03/09/2025 14:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250903:nRSC8804Xa&default-theme=true

RNS Number : 8804X  Hemogenyx Pharmaceuticals PLC  03 September 2025

3 September 2025

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

Exercise of Warrants and Issue of Equity

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has received a
notice to exercise warrants over 250,000 new ordinary shares in the Company
(the "Warrant Shares").

The Warrant Shares are being issued pursuant to the exercise of warrants
granted and announced on 8 May 2025. As announced, the exercise price of the
warrants ("Exercise Price") is subject to adjustment in certain circumstances,
as set out in the warrant instrument, including a reset of the Exercise Price
(as defined therein) if the Company completes a share issuance (or other
transaction granting rights to subscribe for equity securities) during the
Exercise Period (as defined therein) at a price lower than the Exercise Price.
As such, the Exercise Price was adjusted to 180p. Subscription monies of
£450,000 have been received by the Company in respect of the exercise.

Admission and Total Voting Rights

Application will be made for the Warrant Shares, which will rank pari
passu in all respects with the existing Ordinary Shares of the Company, to be
admitted to the FCA official list and to trading on the equity shares
(transition) category of the Official List maintained by the FCA and to
trading on the main market for listed securities of the LSE, which is expected
to occur on or around 8.00 a.m. on 9 September 2025 ("Admission").

Upon Admission (and including the 316,667 new ordinary shares being issued as
announced on 26 August 2025), the total number of issued shares and the total
number of voting rights in the Company will be 5,293,896.

The above figure of 5,293,896 should be used by shareholders in the Company as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
share capital of the Company under the Financial Conduct Authority's
Disclosure Guidance and Transparency Rules.

The Company will keep the market informed of future developments as trials
proceed.

 

Enquiries:

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)
 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl
 Peterhouse Capital Limited                                      Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City .

The Company is a clinical stage biopharmaceutical group developing new
medicines and treatments to treat blood and autoimmune diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary product
candidates, as well as platform technologies that it uses as engines for novel
product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOELJMTTMTAMBAA